Kirkland & Ellis LLP advised Los Angeles-based global investment firm The Gores Group in its definitive agreement under which a subsidiary of Mallinckrodt plc (NYSE: MNK), a leading specialty biopharmaceutical company, will acquire Therakos, Inc. from The Gores Group in a transaction valued at approximately $1.325 billion. Therakos is a leading immunotherapy company. Subject to customary closing conditions, the parties expect the transaction to be completed in the latter part of the third quarter of 2015. The full release can be found here.
The Kirkland team included corporate partners Rick Madden, Damon Fisher, and Carol Anne Huff, and tax partner Mike Beinus.